This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ecancer
T

ASCO® 2024 Insights: "IMROZ - A Ph3 Study of Isatuximab + VRd vs. VRd for Transplant-Ineligible NDMM"

By ecancer FEATURING Thierry Facon
By ecancer FEATURING Thierry Facon
108 views
June 24, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

ecancer

M. Al Malki, S. Devine

42 views

·

3 months ago
09:04

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple …

ecancer

X. Leleu

77 views

·

4 months ago
27:49

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

704 views

·

4 months ago
View All

Recommended

21:05

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views

·

8 months ago
17:52

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

·

7 months ago
16:42

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

·

10 months ago
24:35

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views

·

4 months ago
35:27

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

·

4 months ago
15:35

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views

·

3 months ago
28:20

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

680 views

·

6 months ago
17:46

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

1.4K views

·

10 months ago
24:23

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views

·

5 months ago
20:23

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views

·

4 months ago
15:00

New

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

273 views

·

1 week ago
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

883 views

·

7 months ago
09:51

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

465 views

·

8 months ago
13:15

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

2024 ASCO® Annual Meeting Insights Hub

O. Landgren

414 views

·

5 months ago
36:10

Highlights in Plasma Cell Disorders From ASCO® and EHA

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

466 views

·

4 months ago
13:47

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

395 views

·

5 months ago
22:33

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

208 views

·

3 months ago
19:24

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - Incorpo…

Insights from 2023 ASH Annual Meeting

P. Richardson

760 views

·

10 months ago
06:19

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Insights from 2023 ASH Annual Meeting

B. Derman

760 views

·

10 months ago
19:20

Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment

2024 ASCO® Annual Meeting Insights Hub

A. Jakubowiak

291 views

·

3 months ago
AUTOPLAY